Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glimepiride - Sanofi

Drug Profile

Glimepiride - Sanofi

Alternative Names: Amarel; Amaril; Amaryl; HOE-490; Roname

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Lacer; Sanofi; Shandong Zibo - Xinhua - Chemferm (JV)
  • Class Antihyperglycaemics; Small molecules; Sulfonylureas
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Jan 2014 Sanofi completes the phase III RECOMMEND trial in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, Guatemala, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and the United Arab Emirates (NCT01459809)
  • 16 Feb 2012 Phase-III clinical trials in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and United Arab Emirates (Oral) after February 2012
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top